News and Literature
Nura Bio is pursuing exciting and rapidly evolving science. See our latest news and relevant research in this field.
Latest News
Literature
- Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease Neuron
- SARM1 signaling mechanisms in the injured nervous system Current Opinion in Neurobiology
- Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1 Cell Reports
- dSarm/Sarm1 is required for activation of an injury-induced axon death pathway Science
- Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly Neuron
- Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1 Brain
- The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD(+) Cleavage Activity that Promotes Pathological Axonal Degeneration Neuron
- Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice Brain
- Programmed axon degeneration: from mouse to mechanism to medicine Nature Reviews Neuroscience
- Sarm1 Deletion, but Not Wld(S), Confers Lifelong Rescue in a Mouse Model of Severe Axonopathy Cell Reports
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
Nura Bio Expands Leadership Team with C-Suite Appointments
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million
Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746
Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON
Marc Freeman wins first annual Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing
Nura Bio Announces publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS